HC Wainwright Reaffirms “Buy” Rating for Iterum Therapeutics (NASDAQ:ITRM)

Iterum Therapeutics (NASDAQ:ITRM)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 289.61% from the stock’s previous close.

Iterum Therapeutics Trading Down 7.8 %

NASDAQ:ITRM opened at $1.54 on Tuesday. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 3.63. Iterum Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.50. The firm has a market capitalization of $25.30 million, a P/E ratio of -0.52 and a beta of 2.36. The company has a fifty day moving average of $1.52 and a 200 day moving average of $1.50.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.08. On average, research analysts predict that Iterum Therapeutics will post -1.75 earnings per share for the current year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.